Who are Alteplase for Injection's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Krazati, Lumakras, Dexilant, Nexium, Pantoprazole Sodium, Protonix.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/alteplase-for-injection.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Alteplase for Injection — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Alteplase for Injection (Alteplase for Injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fibrinolytic. Area: Cardiovascular.

phase 2 Fibrinolytic tPA Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Alteplase for Injection (Alteplase for Injection) — Angde Biotech Pharmaceutical Co., Ltd.. Alteplase for Injection is a tissue plasminogen activator that works by dissolving blood clots.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Alteplase for Injection TARGET	Alteplase for Injection	Angde Biotech Pharmaceutical Co., Ltd.	phase 2	Fibrinolytic	tPA
Krazati	ADAGRASIB	Bristol-Myers Squibb	marketed		GTPase KRas	2022-01-01
Lumakras	SOTORASIB	Amgen	marketed		GTPase KRas	2021-01-01
Dexilant	DEXLANSOPRAZOLE	Takeda	marketed	Proton Pump Inhibitor [EPC]	(H+, K+)-ATPase	2009-01-01
Nexium	esomeprazole	AstraZeneca	marketed	Proton pump inhibitor (PPI)	Potassium-transporting ATPase	2001-02-20
Pantoprazole Sodium	Pantoprazole Sodium	Pfizer	marketed	Proton pump inhibitor (PPI)	(H+, K+)-ATPase enzyme	2000-01-01
Protonix	Pantoprazole Sodium	Baxter	marketed	Proton pump inhibitor (PPI)	(H+, K+)-ATPase enzyme system	2000-01-01

Recent regulatory actions (last 90 days)

2026-04-22 — Protonix · FDA · approved · US · Baxter

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-12-07 — Pantoprazole Sodium · 7544370*PED · US

Sponsor landscape (Fibrinolytic class)

Angde Biotech Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Alteplase for Injection — Competitive Intelligence Brief. https://druglandscape.com/ci/alteplase-for-injection. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing